Dolcetti and his colleague Thomas reported an oil‐in‐water nanoemulsion system (200 nm) conjugated with targeting mAb to Clec9a expressed by cross presenting cDC1s.[54] By encapsulating tumor antigens, the nanoemulsion vaccine formulation in the absence of additional adjuvants was able to target and activate cross‐presenting Clec9a+DCs, thereby enhancing induction of antigen specific T cells. The gene discussed is CLEC9A; the disease is neoplasm.